Alexion Pharma (NASDAQ: ALXN) announced that the European Commission has approved Strensiq (asfotase alfa) for long-term enzyme replacement therapy in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE